BioCryst Pharmaceuticals Inc (BCRX) - Total Liabilities
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has total liabilities worth $1.02 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of BioCryst Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
BioCryst Pharmaceuticals Inc - Total Liabilities Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
BioCryst Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aguas Andinas S.A
SN:AGUAS-A
|
Chile | CL$1.82 Trillion |
|
BTG Hotels Group Co Ltd
SHG:600258
|
China | CN¥12.28 Billion |
|
African Rainbow Minerals Ltd
JSE:ARI
|
South Africa | ZAC14.20 Billion |
|
COUNTRY GARDEN SVDL-0001
F:75H
|
Germany | €33.49 Billion |
|
Mr Price Group Ltd
JSE:MRP
|
South Africa | ZAC18.97 Billion |
|
ODFJELL DRILL.LTD. DL-01
F:OD3
|
Germany | €1.25 Billion |
|
SK Bioscience Co Ltd
KO:302440
|
Korea | ₩847.96 Billion |
|
Driven Brands Holdings Inc
NASDAQ:DRVN
|
USA | $3.36 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down BioCryst Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is BioCryst Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioCryst Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual total liabilities of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $633.31 Million | -34.46% |
| 2024-12-31 | $966.35 Million | -0.63% |
| 2023-12-31 | $972.49 Million | +15.14% |
| 2022-12-31 | $844.60 Million | +21.50% |
| 2021-12-31 | $695.14 Million | +96.38% |
| 2020-12-31 | $353.98 Million | +158.32% |
| 2019-12-31 | $137.03 Million | +40.39% |
| 2018-12-31 | $97.61 Million | +3.30% |
| 2017-12-31 | $94.49 Million | +7.05% |
| 2016-12-31 | $88.27 Million | +14.89% |
| 2015-12-31 | $76.83 Million | +25.46% |
| 2014-12-31 | $61.24 Million | +22.50% |
| 2013-12-31 | $49.99 Million | -13.65% |
| 2012-12-31 | $57.89 Million | -14.11% |
| 2011-12-31 | $67.40 Million | +53.38% |
| 2010-12-31 | $43.94 Million | -21.42% |
| 2009-12-31 | $55.92 Million | +46.15% |
| 2008-12-31 | $38.27 Million | -50.82% |
| 2007-12-31 | $77.81 Million | +64.40% |
| 2006-12-31 | $47.33 Million | +15.98% |
| 2005-12-31 | $40.81 Million | +1201.96% |
| 2004-12-31 | $3.13 Million | +90.08% |
| 2003-12-31 | $1.65 Million | +40.63% |
| 2002-12-31 | $1.17 Million | -48.63% |
| 2001-12-31 | $2.28 Million | -75.58% |
| 2000-12-31 | $9.35 Million | +367.27% |
| 1999-12-31 | $2.00 Million | +42.86% |
| 1998-12-31 | $1.40 Million | +16.67% |
| 1997-12-31 | $1.20 Million | -29.41% |
| 1996-12-31 | $1.70 Million | -5.56% |
| 1995-12-31 | $1.80 Million | +12.50% |
| 1994-12-31 | $1.60 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more